# Debate Matchup Judgment Report

**Claude Sonnet 4.6 (high)** vs **GPT-5.5 (high)**

- Paired result: **Tie**
- Mean entertainment: `7.50 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Governments should permit carefully regulated psychedelic-assisted therapy outside narrow clinical-trial settings for severe treatment-resistant conditions.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0349__claude-sonnet-4-6-adaptive__gpt-5.5-high__s0__tpl_placement_active_20260320f.md): PRO = **Claude Sonnet 4.6 (high)**, CON = **GPT-5.5 (high)**
- [Debate B transcript](../../../transcripts/prop_0349__gpt-5.5-high__claude-sonnet-4-6-adaptive__s1__tpl_placement_active_20260320f.md): PRO = **GPT-5.5 (high)**, CON = **Claude Sonnet 4.6 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0349__claude-sonnet-4-6-adaptive__gpt-5.5-high__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **Claude Sonnet 4.6 (high)**, CON = **GPT-5.5 (high)**
- Judged result: Split `2-1` for **GPT-5.5 (high)**.
- Entertainment scores: `8`, `6`, `8`
- Mean signed raw margin (PRO+): `-0.57`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | A = Claude Sonnet 4.6 (high) (PRO); B = GPT-5.5 (high) (CON) | GPT-5.5 (high) | -1.8 | -1.50 | 8.0 |
| Grok 4.3 | A = GPT-5.5 (high) (CON); B = Claude Sonnet 4.6 (high) (PRO) | GPT-5.5 (high) | -1.2 | -1.44 | 6.0 |
| Qwen 3.6 Max Preview | A = GPT-5.5 (high) (CON); B = Claude Sonnet 4.6 (high) (PRO) | Claude Sonnet 4.6 (high) | +1.3 | +1.30 | 8.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview** (A = Claude Sonnet 4.6 (high) (PRO); B = GPT-5.5 (high) (CON)): Side B won by systematically dismantling Side A's mechanisms and effectively defending its own alternative. Side B successfully exposed a contradiction in Side A's moral urgency (pointing out Side A conceded the most suicidal patients would be excluded) and drew a decisive, principled line between exceptional hospital-based access and scaling a broad therapeutic market before protocols are settled.
  Most decisive rebuttal noted: Side B's Rebuttal 2 takedown of Side A's SSRI analogy, arguing persuasively that the provider and the therapy are the intervention itself in psychedelics, making it far riskier to scale to ordinary practitioners without established protocols.
- **Grok 4.3** (A = GPT-5.5 (high) (CON); B = Claude Sonnet 4.6 (high) (PRO)): Side A won by sharpening the distinction between narrow, data-tied exceptions and scaled ordinary-provider practice, exposing PRO's moral-urgency claims as inconsistent with their own exclusions, and grounding the intervention-specific risks (provider vulnerability, mechanism dependence) without overclaiming evidence. B's scale-vs-bottleneck argument was undercut once those exclusions were conceded.
  Most decisive rebuttal noted: A's Rebuttal 2 and closing on the provider-quality distinction and controlled-exception vs market-normalization line, which neutralized B's hospital-access concession.
- **Qwen 3.6 Max Preview** (A = GPT-5.5 (high) (CON); B = Claude Sonnet 4.6 (high) (PRO)): PRO wins by successfully collapsing CON's hospital-based alternative into a concession of the motion's core principle, framing the dispute as one of scale and throughput rather than a binary safety clash. PRO effectively leverages the underground displacement argument and handles pressure with strategic concessions that preserve the moral urgency of the access bottleneck. CON makes strong substantive points about the difficulty of scaling therapy-dependent interventions and the epistemic risks of premature normalization, but repeated clipping across three turns hinders full argument development and leaves key comparative burdens under-answered. CON also struggles to neutralize PRO's framing that regulated practice is the necessary mechanism to generate the mature evidence CON demands. PRO's closing crystallizes the comparative stakes and the decisive gap in CON's case more cleanly.
  Most decisive rebuttal noted: PRO's response to the elite-team pressure, turning the circularity argument against CON by arguing that carefully regulated practice is the only viable mechanism to generate mature real-world evidence, effectively neutralizing CON's demand for pre-existing proof while maintaining risk-stratified guardrails.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0349__gpt-5.5-high__claude-sonnet-4-6-adaptive__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **GPT-5.5 (high)**, CON = **Claude Sonnet 4.6 (high)**
- Judged result: Split `2-1` for **GPT-5.5 (high)**.
- Entertainment scores: `8`, `7`, `8`
- Mean signed raw margin (PRO+): `+0.30`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | A = GPT-5.5 (high) (PRO); B = Claude Sonnet 4.6 (high) (CON) | GPT-5.5 (high) | +1.2 | +1.00 | 8.0 |
| Grok 4.3 | A = Claude Sonnet 4.6 (high) (CON); B = GPT-5.5 (high) (PRO) | Claude Sonnet 4.6 (high) | -1.5 | -1.80 | 7.0 |
| Qwen 3.6 Max Preview | A = Claude Sonnet 4.6 (high) (CON); B = GPT-5.5 (high) (PRO) | GPT-5.5 (high) | +1.2 | +1.20 | 8.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview** (A = GPT-5.5 (high) (PRO); B = Claude Sonnet 4.6 (high) (CON)): Side A wins by effectively neutralizing Side B's practical objections. When B argued that the necessary infrastructure and workforce do not exist for regulated access, A sharply pointed out that B's own alternative (expanded compassionate-use trials) requires the exact same infrastructure. A also successfully framed trial exclusions as often based on research constraints (geography, arbitrary timing) rather than purely safety, making B's reliance on trials insufficient for addressing severe clinical need.
  Most decisive rebuttal noted: Side A's Q2 and subsequent handling of Side B's answer was decisive. A challenged B to name a safeguard exclusive to trials; B named DSMBs and pre-specified stopping rules, but A expertly pointed out in closing that the authority to pause a program and monitor safety are regulatory tools, not magic exclusive to "research" labels.
- **Grok 4.3** (A = Claude Sonnet 4.6 (high) (CON); B = GPT-5.5 (high) (PRO)): Side A won by establishing and defending the decisive burden that PRO cannot deliver genuinely careful regulation without trial-derived data, established standards, and independent stopping rules; PRO's phased-permission and hospital analogies were repeatedly shown circular or incomplete, while A's pressure-question answers and closing crystallized why expanded compassionate-use trials preserve the safeguards the motion itself requires.
  Most decisive rebuttal noted: A's A1/A2 answers on certification and exclusion criteria plus the DSMB contrast in rebuttal 2 and closing, which neutralized PRO's "regulatory tools are sufficient" claim without widening the debate.
- **Qwen 3.6 Max Preview** (A = Claude Sonnet 4.6 (high) (CON); B = GPT-5.5 (high) (PRO)): Side B (PRO) wins by more clearly framing the core tradeoff: the non-neutral harm of delay versus the manageable risks of a regulated pathway. PRO successfully turned CON's caution argument, demonstrating that regulatory frameworks can replicate trial safeguards (screening, pause authority, audits) while avoiding the structural access limits of research protocols. CON's strongest point—the unique value of DSMBs and pre-specified stopping rules—was substantive, but PRO adequately answered it by noting regulatory bodies can also halt programs and that CON's demand for mature data before any access creates a circular prohibition. PRO's closing crystallization ("legal form decides who gets help") gave a cleaner, more decisive path to victory. Both sides were disciplined and avoided fake precision, but PRO's comparative weighing and rhetorical clarity edged out CON's technically sound but narrower focus on implementation gaps.
  Most decisive rebuttal noted: The exchange over trial-exclusive safeguards. CON's Q2 and R2 identification of independent oversight with pre-specified stopping rules (DSMBs) versus post-hoc registries was a sharp, concrete challenge. PRO's response—arguing that regulatory licensing can include mandatory pause authority, that trial exclusions often reflect research design rather than safety, and that demanding real-world data before permitting supervised access is a circular trap—effectively neutralized the point while reinforcing PRO's core comparison of risks.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0349`
- Side-swap group ID: `prop_0349__claude-sonnet-4-6-adaptive__gpt-5.5-high__tpl_placement_active_20260320f`
- Raw paired winner: **Tie**
- Mean normalized margin for Claude Sonnet 4.6 (high): `-0.34`
- Complete side swap: `yes`
- Included in ratings: `yes`
